NASDAQ:CLCD Investor Notice: Investigation of Takeover of CoLucid Pharmaceuticals Inc
The acquisition of CoLucid Pharmaceuticals Inc is under investigation over potential wrongdoing. The investigation was announced for investors, who currently hold NASDAQ:CLCD shares, concerning whether the takeover of CoLucid Pharmaceuticals Inc by Eli Lilly and Company for $46.50 per share is unfair.
View full press release